For research use only. Not for therapeutic Use.
NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections[1][2].
NP213 (500-1000 μg/mL; 18 hours) increases the number of PI-stained T. rubrum NCPF0118 cells in samples. This results suggests that NP213 is fungicidal and the mechanisms of action involved membrane permeabilization[1].NP213 is against T. rubrum NCPF0118, shows different MIC values against T. rubrum NCPF0118, and the MICs varies depending on the source of the keratin. The MIC values are 16-32 mg/L, 125 mg/L, and 250 mg/L for NP213 in 1640 media containing human nail Keratin, human skin Keratin and Lamb’s wool Keratin, respectively[1].NP213 TFA (2-3 hours; 0-8 μg/ml) has great activity against clinically relevant yeast, including candida spp, Cryptococcus spp and Trichosporon spp. For all 122 yeast isolates, with the median MIC100 values of 1-2 µg/ml[3].
NP213 TFA (25 mg/kg) is well tolerated in mice. In Murine models of acute disseminated candidiasis, NP213 is tolerated and efficacious and exhibits a half-life of approximately 4.5 h[3].
| Catalog Number | I045897 |
| Synonyms | 2-[3-[(2S,5S,8S,11S,14S,17S,20S)-5,8,11,14,17,20-hexakis[3-(diaminomethylideneamino)propyl]-3,6,9,12,15,18,21-heptaoxo-1,4,7,10,13,16,19-heptazacyclohenicos-2-yl]propyl]guanidine;2,2,2-trifluoroacetic acid |
| Molecular Formula | C44H85F3N28O9 |
| Purity | ≥95% |
| InChI | InChI=1S/C42H84N28O7.C2HF3O2/c43-36(44)57-15-1-8-22-29(71)65-24(10-3-17-59-38(47)48)31(73)67-26(12-5-19-61-40(51)52)33(75)69-28(14-7-21-63-42(55)56)35(77)70-27(13-6-20-62-41(53)54)34(76)68-25(11-4-18-60-39(49)50)32(74)66-23(30(72)64-22)9-2-16-58-37(45)46;3-2(4,5)1(6)7/h22-28H,1-21H2,(H,64,72)(H,65,71)(H,66,74)(H,67,73)(H,68,76)(H,69,75)(H,70,77)(H4,43,44,57)(H4,45,46,58)(H4,47,48,59)(H4,49,50,60)(H4,51,52,61)(H4,53,54,62)(H4,55,56,63);(H,6,7)/t22-,23-,24-,25-,26-,27-,28-;/m0./s1 |
| InChIKey | RAWZYRRHFHWWGX-UZTLYUDCSA-N |
| SMILES | C(CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCN=C(N)N)CCCN=C(N)N)CCCN=C(N)N)CCCN=C(N)N)CCCN=C(N)N)CN=C(N)N.C(=O)(C(F)(F)F)O |
| Reference | [1]. Mercer DK,et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii [2]. Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools.Probiotics Antimicrob Proteins. 2016 Jun;8(2):85-101. [3]. Novamycin®/NP339 Technology Summary |
